To review the incidence, management, and current understanding of the pathophysiology of β-lactam–induced neutropenia and to critically evaluate the practicality and safety of direct substitution to an alternative β-lactam in the setting of this reaction. A literature analysis using the PubMed and Ovid search engines (July 1968 to October 2020) was performed using the search terms neutropenia, leukopenia, β-lactam, nonchemotherapy, agranulocytosis, and G-CSF (granulocyte colony-stimulating factor). The included English-language studies evaluated the incidence, mechanism, and/or management of β-lactam–induced neutropenia in pediatric or adult patients. Drug-induced neutropenia is a well-documented adverse reaction of β-lactam antibiotics, with an incidence of approximately 10% following at least 2 weeks of intravenous therapy. However, multiple gaps in knowledge remain in the mechanism of pathophysiology and optimal management of this reaction. Both direct toxic and immune-mediated mechanisms have been implicated. Although the cornerstone of management includes cessation of the offending agent, controversy exists on the appropriateness of direct substitution or future use of an alternative β-lactam. Given the frequency of use and superiority of β-lactams over alternative therapy for several infectious disease states, practical recommendations are needed on the management and safe use of β-lactams following β-lactam–induced neutropenia. Future use of β-lactams with differing R1 side chains, particularly those from a separate class, should not be deemed contraindicated following β-lactam–induced neutropenia and may be considered when indicated, with close laboratory monitoring.
15 August 2018 in Journal of Clinical Pharmacy and Therapeutics
What is known and objective With the advent of antiretroviral therapy and the resultant decrease in mortality among adults living with human immunodeficiency virus (HIV), there is now an increased incidence of obesity and obesity‐related comorbidities in these patients. Bariatric surgery is becoming an increasingly common treatment option for patients who are classified as clinically obese. There are limited data regarding the use of antiretroviral therapy in patients who have undergone bariatric surgery. The purpose of this review was to evaluate the available literature regarding antiretroviral therapy and pharmaceutical properties in this special population. Methods Literature review was performed through PubMed, utilizing search terms of bariatric surgery, sleeve gastrectomy, Roux‐en‐Y, HIV infection, obesity and antiretroviral. Direct medical information requests to antiretroviral pharmaceutical manufacturers were also completed. Results Several case series and case reports have been published which demonstrate minimal risk of complications and maintenance of virologic suppression in the vast majority of patients. Bariatric surgery appears to be an effective mechanism for assistance in controlling obesity in patients infected with HIV; however, numerous factors may impact the safe and effective use of antiretroviral therapy. What is new and conclusion Due to the physiologic changes and postoperative management following bariatric surgery, evaluation of the patients’ medication regimens must be considered and several factors should be taken into account when choosing the appropriate antiretroviral regimen for these patients. Furthermore, communication between the patients’ surgeon, HIV provider and a clinical pharmacist should occur prior to surgery to ensure the patient is optimized to achieve the best outcome including maintaining virologic suppression.
Nontuberculous mycobacteria (NTM) can cause a variety of infections, including serious pulmonary disease. Treatment encompasses polypharmacy, with a targeted regimen of 2–5 active medications, depending on site of infection, species, and clinical characteristics. Medications may include oral, intravenous, and inhalational routes. Medication acquisition can be challenging for numerous reasons, including investigational status, limited distribution models, and insurance prior authorization. Additionally, monitoring and managing adverse reactions and drug interactions is a unique skill set. While NTM is primarily medically managed, clinicians may not be familiar with the intricacies of medication selection, procurement, and monitoring. This review offers insights into the pharmacotherapeutic considerations of this highly complex disease state, including regimen design, medication acquisition, safety monitoring, relevant drug–drug interactions, and adverse drug reactions.
2 March 2023 in Antimicrobial Stewardship & Healthcare Epidemiology
Background: Nurses perform several functions that are integral for antimicrobial stewardship (AMS). However, nurses are underrepresented in research and underutilized in implementation of AMS interventions. The objective of this pilot study was to assess the effect of asynchronous microlearning on inpatient nursing staff knowledge, attitudes, and practices (KAP) regarding AMS principles. Methods: A team of pharmacists, physicians, and nurses developed 9 case-based, multiple-choice questions with accompanying educational explanations on associated AMS principles. One case was delivered to participants daily via an institutional web-based application (QuizTime). A KAP survey with 20 questions on a 5-point Likert scale was administered before and after the intervention. Survey results were compared using a Wilcoxon signed-rank test. Results: Participants’ mean survey score after the intervention demonstrated statistically significant improvement for 18 (90%) of 20 items compared to before the intervention. Participants’ confidence improved in key AMS activities: (1) differentiating between colonization and infection (mean difference, 0.63; P < .001), (2) identifying unnecessary urine cultures and inappropriate treatment of urinary tract infections (mean difference, 0.94; P < .001), (3) recognizing opportunities for intravenous to oral therapy conversion (mean difference, 1.07; P < .001), and (4) assessing for antibiotic-associated adverse effects (mean difference, 0.54; P < .001). Conclusions: Nursing education provided through an asynchronous, microlearning format via a mobile platform resulted in statistically significant improvement in most KAP topics. Nurses are integral members of a multidisciplinary AMS team, and novel education methods can help equip them with the necessary AMS tools. This pilot study forms the basis for expanded AMS educational efforts in all healthcare professionals.
10 December 2025 in Antimicrobial Stewardship & Healthcare Epidemiology
Objective: To evaluate the impact of a guidance document on treatment decisions and clinical outcomes for infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) and Stenotrophomonas maltophilia. Design: This was a single-center, retrospective, quasi-experimental, pre- and post-intervention study. The primary outcome was adherence to antibiotic selection and dosing as recommended by the guidance document. Secondary outcomes included clinical efficacy, readmission within 90 days, all-cause 30-day mortality, 90-day microbiologic recurrence, and antibiotic-associated adverse effects. Setting: The study was conducted at a large, academic medical center in the Southeastern United States. Participants: The study included adult patients who were admitted to our institution from November 2018 to June 2024 who grew CRAB or S. maltophilia from any culture and were definitively treated. Intervention: This study included an institution specific treatment algorithm for the treatment of infections caused by resistant gram-negative organisms published on June 1 st , 2022, on our institution’s antimicrobial stewardship website. Results: Twenty-two patients with CRAB (14 pre- and 8 post-intervention) and 150 with S. maltophilia (75 pre- and 75 post-intervention) were evaluated. For CRAB, 0 (0%) patients in the pre-intervention group and 5 (62.5%) in the post-intervention group met the primary outcome ( P < .001). For S. maltophilia, 21 (28%) patients in the pre-intervention group compared to 38 (50.7%) in the post-intervention group met the primary outcome ( P < .004). Secondary outcomes did not differ significantly pre- and post-intervention. Conclusions: These findings demonstrate that implementing a local treatment guideline based on IDSA guidance may increase the utilization of evidence-based directed antimicrobial therapy for CRAB and S. maltophilia.